Biologiska läkemedel och ATMP på agendan när forskare samlades i Köpenhamn

Under onsdagen arrangerades New Horizons in Biologics & Bioprocessing. Här ser du bilder från eventet.

Vicore tar in 782 miljoner för sin lungfibroskandidat

Vicore Pharma har beslutat att ta in upp till 782 miljoner kronor i en företrädesemission för att finansiera fortsatt utveckling av bolagets behandling för idio...

Efficient use of blood plasma

Blood plasma is an indispensable resource in the production of life-saving medicines. It is in high demand on global markets. To make more efficient use of this...

Novo Nordisk appoints Mike Doustdar as new CEO

The Danish pharmaceutical giant Novo Nordisk has appointed Mike Doustdar as its new CEO. At the same time, the company announced it was lowering its forecasts –...

Microscope and measuring machine in one

ZEISS O-INSPECT duo covers two essential applications in quality assurance.

Xspray fyller på inför USA-lansering – tar in 135 miljoner

Forskningsbolaget Xspray Pharma har beslutat att ta in 135 miljoner kronor via en nyemission med företrädesrätt för befintliga aktieägare.

ZEISS at EMO Hannover 2025

Experience some of the most exciting highlights from our ZEISS product portfolio.

FDA approves Gilead’s HIV injection: “Historic day”

Gilead Sciences’ preventive HIV drug, lenacapavir, was approved on Wednesday by the U.S. Food and Drug Administration (FDA), sparking new hope for finally break...

One System, Three Contrasting Techniques

ZEISS Axioscan 7 clinical - your digital slide scanner for diagnostics and clinical research.

New Insights into Microscopy

Watch the recording of our free webinar.

Lund University’s record-breaking recruitment – attracting researchers from around the world

The Swedish university is launching its largest international recruitment effort ever, aiming to hire 25 researchers globally, including several in the medical field.

Immunterapibolag tar in 339 miljoner

Immunterapibolaget Asgard Therapeutics har tagit in 30 miljoner euro, motsvarande omkring 339 miljoner kronor, i en finanseringsrunda.

Uppgifter: Sanofi tar in bud på konsumenthälsodivision

Den franska läkemedelsjätten Sanofi ska enligt uppgifter ha bett om initiala bud för sin konsumenthälsoverksamhet, som är värderad till runt 20 miljarder dollar.

Artificial intelligence in radiology – “Risk prediction is very exciting”

A growing number of solutions based on artificial intelligence are being developed and used in healthcare. According to Sophia Zackrisson, Professor of Radiolog...

Novo Nordisk cuts ties with Hims & Hers after Wegovy dispute

Novo Nordisk is ending its collaboration with Hims & Hers Health due to concerns about the company’s sales and marketing practices related to the weight-loss drug Wegovy.

A tiny animal with great importance

From the mythical Ganges River to the less sacred, but considerably cleaner waters in KI's aquariums in Solna. The little zebrafish has made an unconscious care...

List: The coolest names in biotech

Hairy beasts, volcanic material and space strolling stand out on a US list of the best biotech company names, and on a list of the coolest names for pharmaceuti...

Medivirs licenspartner avbryter cancerprogram

Medivirs amerikanska licenspartner Tango Therapeutics har beslutat att avbryta utvecklingen av cancerkandidaten TNG348.

Raise-In AB

Explore the possibilities of the new ZEISS METROTOM 800 320 kV

Free ZEISS webinar July 10, 9:00-9:45 AM and 5:00-5:45 PM.

Pharma Outsourcing – Find the right partner

Quretech tar in 14 miljoner för utveckling av ny antibiotika

Umeåbaserade Quretech Bio har säkrat ett kapitaltillskott på 14 miljoner kronor till fortsatt utveckling av nya antibiotika och infektionbehandlingar för att bi...

Sepsisbolag tar in kapital

Bioteknikbolaget Aptahem, som utvecklar en behandling mot sepsis, har beslutat om en företrädesemission som kan ge bolaget upp till 34,6 miljoner kronor.

The race between new alzheimer’s drugs Kisunla and Leqembi heats up

Kisunla or Leqembi? The rivalry between Eli Lilly and Bioarctic is intensifying. Where one drug gains approval, the other falls behind. Here's a look at the mar...